Stock shortage alert: Guanfacine ADHD medication unavailable until may

The Department of Health and Social Care (DHSC) published a notification regarding the shortage of Guanfacine 2mg and 3mg modified-release tablets has
raised concerns within the healthcare community.

This critical medicine supply notification, issued on March 28th, projects the unavailability of these tablets until the week commencing May 6, 2024.

Guanfacine tablets, commonly prescribed to alleviate symptoms of hyperactivity and impulsivity while enhancing attention and concentration, play a vital role in
managing conditions like attention deficit hyperactivity disorder (ADHD).

However, the scarcity of these specific strengths poses challenges for patients reliant on this medication.

Last year, several countries across the globe experienced shortages of medications for the treatment of attention deficit hyperactivity disorder (ADHD)including
the UK, the US and Australia.

Community Pharmacy England (CPE) has cautioned that while alternative strengths of Guanfacine remain accessible, they may not adequately meet the heightened demand,
potentially resulting in treatment interruptions for patients.